EHA 2022 | Optimal PCR responses and survival of patients with CBF-AML treated with FLAG-IDA or FLAG-GO
Jayastu Senapati, MBBS, MD, MD Anderson Cancer Center, Houston, TX, comments on the results of a study investigating the factors affecting early and late optimal PCR responses and survival in patients with core binding factor acute myeloid leukemia (CBF-AML) treated with fludarabine, cytarabine, and GCSF with idarubicin (FLAG-IDA), or with gemtuzumab ozogamicin (FLAG-GO). The study found that patients treated with FLAG-GO had a better optimal PCR response both after the first cycle and the last cycle of therapy, and also had a better relapse-free survival (RFS) and overall survival (OS). In addition, kinase mutations were not found to have a significant impact on FLAG-based treatment regimens. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
